CDC Director Delays COVID Vaccine Study

A planned study from the Centers for Disease Control and Prevention (CDC) aimed at showcasing the benefits of COVID-19 vaccines has been put on hold. Acting Director Dr. Jay Bhattacharya has reportedly delayed the release of the report, citing concerns about its methodology. This decision has raised questions and sparked debate among public health experts.

Concerns Over Study Methodology

The study, originally slated for release in March 2026 in the CDC’s Morbidity and Mortality Weekly Report (MMWR), focused on the vaccine’s effectiveness in reducing hospitalizations and emergency department visits among healthy adults during the 2025 winter season. However, spokesperson Andrew Nixon stated that Dr. Bhattacharya “expressed concerns about the observational method used in this study to calculate vaccine effectiveness.”

Nixon further explained, “It’s routine for CDC leadership to review and flag concerns about MMWR papers, especially relating to their methodology, leading up to planned publication.” He added that Dr. Bhattacharya wants to ensure the paper employs the most appropriate methodology. Despite these assurances, critics point out that the questioned method, known as a test-negative design, has been used for years to assess vaccine effectiveness against respiratory viruses and was even utilized in a 2021 New England Journal of Medicine study on similar topics.

Broader Implications and Political Interference

Dr. Bhattacharya was appointed to lead the CDC in February, serving until a permanent director is nominated by President Donald Trump. This delay comes at a time when leading health officials within the Trump administration have reportedly voiced criticism of traditional vaccine research methods. Many public health experts view this delay with suspicion.

Dr. Fiona Havers, a former medical epidemiologist who resigned from the CDC, expressed concern that this action might be part of a larger effort to sow doubt about vaccine safety and accessibility. “I’m not saying that they haven’t stopped other publications or forced changes to them, but to wholesale stop this report from coming out, given that it is such a well-established platform and such a well-established methodology, does strike me as a new level of political interference into CDC’s scientific process,” she stated.

This concern is further fueled by a previous call from former FDA regulator Vinay Prasad for new restrictions on approved COVID-19 vaccines from Novavax and Moderna. That controversy coincided with an announcement about more stringent vaccine approval guidelines, following reports of deaths allegedly linked to a COVID-19 vaccine.

Ensuring Sound Science

Despite the controversy, Nixon reiterated the CDC’s commitment to scientific integrity, stating that “Dr. Bhattacharya wants to make sure that the paper uses the most appropriate methodology for such a study” and that the CDC is “taking time to ensure analyses are methodologically sound and clearly communicated is always preferable to risking error.” The agency emphasizes that ensuring accuracy and clarity in their findings is paramount.